Development of immunotherapy for infections due to Pseudomonas aeruginosa.
D000917:Antibody Formation; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002056:Burns / Q000150:complications; D049673:History, 20th Century; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007167:Immunotherapy / Q000266:history; D011552:Pseudomonas Infections / Q000150:complications / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000145:classification / Q000276:immunology; D014481:United States; D005719:gamma-Globulins
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D005719:gamma-Globulins